Treating PCa cells with C75 increased the expression of FATP1 and CD36, and blocking CD36 with an antibody resulted in increased sensitivity to C75, suggesting that the potency of C75 is affected by FA availability [120]. The gene discussed is SLC27A1; the disease is posterior cortical atrophy.